Rilpivirine Hydrochloride is Used for treating HIV-1 infection in treatment-naive adult patients with low viral load. It was first introduced by Janssen Products Lp in its drug Edurant on May 20, 2011. Another drug containing Rilpivirine Hydrochloride is Edurant Ped.

Rilpivirine Hydrochloride Patents

Given below is the list of patents protecting Rilpivirine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Edurant Ped	US11065198	Dispersible compositions	Oct 23, 2037	Janssen Prods
Edurant	US7125879 (Pediatric)	HIV inhibiting pyrimidines derivatives	Oct 21, 2025	Janssen Prods
Edurant	US7125879	HIV inhibiting pyrimidines derivatives	Apr 21, 2025 (Expired)	Janssen Prods
Edurant Ped	US7125879	HIV inhibiting pyrimidines derivatives	Apr 21, 2025 (Expired)	Janssen Prods
Edurant	US7638522	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile	Apr 14, 2023 (Expired)	Janssen Prods
Edurant	US8080551	HIV inhibiting pyrimidines derivatives	Apr 11, 2023 (Expired)	Janssen Prods
Edurant	US8101629	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile	Aug 09, 2022 (Expired)	Janssen Prods
Edurant	US6838464	2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents	Feb 26, 2021 (Expired)	Janssen Prods
Edurant	US7067522	2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents	Dec 20, 2019 (Expired)	Janssen Prods

Add above patents to watchlist

Rilpivirine Hydrochloride's Family Patents

Full family tree